Clinical Trial

Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea

Completed
View on ClinicalTrials.gov →
Summary
Semaglutide (a GLP-1RA) is approved for type 2 diabetes mellitus T2DM and obesity, but its effect on obstructive sleep apnea OSA remains unclear. To evaluate changes in Apnea-Hypopnea Index (AHI) after 1-week and 4-week semaglutide treatment in T2DM/obesity patients with OSA, we conducted a single-center real-world study (RWS) of 15 patients. Outcomes assessed included AHI, weight, BMI, blood pressure, blood glucose (fasting blood glucose, glycated albumin), liver function, blood lipids, waist circumference, and other metabolic parameters, to provide real-world evidence for semaglutide in OSA management.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-01.
Status change: Recruiting → Completed 2026-04-15
Trial Details
NCT Number NCT07281196
Lead Sponsor Shanghai Fengxian District Central Hospital
Conditions Sleep Apnea Syndrome (OSAS)
Enrollment 15 participants
Start Date 2025-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-20